TMO|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $6.41 | - | - |
| Q2'26 | $6.37 | $6.03 | -5.3% |
| Q1'26 | $5.74 | $5.44 | -5.2% |
| Q4'25 | $6.51 | $6.57 | +0.9% |
| Q3'25 | $5.50 | $5.79 | +5.3% |
| Q2'25 | $5.23 | $5.36 | +2.5% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $12.1B | - | - |
| Q2'26 | $11.8B | $12.0B | +1.5% |
| Q1'26 | $11.8B | $11.0B | -6.7% |
| Q4'25 | $12.1B | $12.2B | +1.2% |
| Q3'25 | - | $11.1B | - |
| Q2'25 | - | $10.9B | - |
Market Data
TMO Stock Snapshot
TMO is currently trading at $592.00, giving Thermo Fisher Scientific Inc. a market cap of 219.63B and a P/E ratio of 31.5. Today's range spans $574.00–$594.26, with shares opening at $578.00 and moving down $1.88 (0.3%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 49/100.
Over the past year TMO has traded between $435.27 and $643.99 - the current price is +36.0% off the 52-week low and -8.1% from the high.
The breakout geometry on TMO is constructive - price at $592.00 (in the upper portion of its 52-week range in $435.27–$643.99), scoring 82/100 (BUY) with neutral sentiment (49/100). (P/E: 31.5) At 219.63B in Healthcare market cap, technical breakouts through prior resistance at this capitalization tier tend to be better validated than in smaller-cap peers - institutional participation means that cleared levels attract follow-through buying rather than immediate fade behavior.
What makes TMO's BUY setup (82/100) particularly actionable at 219.63B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $592.00 (in the upper portion of its 52-week range in $435.27–$643.99), with sentiment running neutral at 49/100, the setup rewards conviction-sized positioning more than it does speculative small bets.
Company Insights: Thermo Fisher Scientific Inc. (TMO)
Thermo Fisher Scientific (TMO) is a global powerhouse in scientific research and laboratory solutions, serving critical segments within Healthcare's Diagnostics & Research industry. The company's extensive portfolio, encompassing life sciences tools, analytical instruments, specialty diagnostics, and biopharma services, underpins its broad market reach. TMO's integrated approach, from foundational lab products to advanced diagnostic capabilities, positions it as a comprehensive partner for scientific advancement and healthcare delivery. Its operations span key international markets, reinforcing its global footprint and diversified revenue streams.
The company's financial performance in recent quarters indicates a positive growth trajectory, particularly in earnings per share. TMO has consistently surpassed analyst expectations for both EPS and revenue, demonstrating robust operational execution and strong demand for its offerings. This pattern of exceeding estimates, evident across Q4 2024 through Q3 2025, highlights the company's ability to navigate market dynamics effectively. Such consistent outperformance suggests a resilient business model capable of driving sustained financial results.
Thermo Fisher Scientific's strategic initiatives and recent innovations underscore its commitment to expanding its leadership in precision healthcare and safety technologies. The introduction of new diagnostic tools, such as accelerated Candida species detection media, and advancements in cryo-electron microscopy for drug discovery, signal ongoing R&D investment. These developments, coupled with its established distribution networks, are designed to enhance its competitive edge and capture future growth opportunities. Investors are closely monitoring the adoption of these new offerings and their impact on future financial performance.
Growth Momentum
Demonstrated consistent EPS acceleration, beating analyst estimates for multiple consecutive quarters.
Revenue trends show an upward trajectory, particularly in the latter half of the reported period.
Historical performance indicates a strong track record of surpassing expectations for both earnings and revenue.
Market Leadership
A global leader in scientific research and laboratory solutions across life sciences, diagnostics, and biopharma.
Comprehensive product portfolio from lab essentials to advanced diagnostic tools provides a competitive advantage.
Established distribution networks, including direct sales and e-commerce, ensure broad market access.
Innovation Pipeline
Recent advancements include new diagnostic tools for accelerated pathogen detection.
Expansion in cryo-electron microscopy capabilities supports drug discovery and development.
Commitment to R&D fuels the introduction of new technologies in precision healthcare and safety.
Valuation & Sentiment
Current P/E ratio stands at approximately 27.84, reflecting market valuation.
Recent price target adjustments, such as Goldman Sachs' reduction to $650, warrant consideration.
Minor institutional selling activity suggests a need for careful monitoring of investor sentiment.
Positioning TMO
Thermo Fisher Scientific's consistent financial outperformance and strategic innovation present a compelling case for long-term investment. Exposure may be increased during periods of strong adoption for new diagnostic tools or following positive earnings reports that exceed expectations. Conversely, significant downward revisions in analyst price targets or broader market pullbacks in the healthcare sector could present opportunities to re-evaluate or reduce exposure.
Risk Factors
Thermo Fisher Scientific faces risks primarily tied to the dynamic nature of scientific innovation, regulatory landscapes, and global supply chain vulnerabilities. Investors should monitor these factors as they can impact demand for its diverse product and service offerings.
- Innovation Lag
The company's success depends on continuous innovation in diagnostics and research tools. A failure to develop or adopt new technologies quickly could lead to market share erosion. This risk would materialize if competitors introduce superior products or if TMO's R&D pipeline underperforms, impacting future revenue growth.
- Regulatory Scrutiny
As a major player in healthcare diagnostics and biopharma services, TMO is subject to stringent regulatory approvals and compliance. Changes in healthcare policies or new regulations could increase operational costs or delay product launches. This risk becomes significant if new compliance requirements are costly or if existing products face regulatory challenges.
- Supply Chain Disruptions
Thermo Fisher's global operations rely on complex supply chains for raw materials and finished goods. Geopolitical events, natural disasters, or supplier issues could disrupt production and delivery. Such disruptions would directly impact TMO's ability to meet customer demand and could lead to increased costs.
- Biopharma Spending
A significant portion of TMO's revenue is derived from serving the biopharmaceutical industry, which can be cyclical. A slowdown in biopharma R&D spending or a contraction in drug development could reduce demand for TMO's instruments and services. This risk would materialize during economic downturns or if the biopharma sector experiences significant funding cuts.
- Integration Challenges
Thermo Fisher has a history of strategic acquisitions. The failure to successfully integrate acquired companies or technologies could lead to underperformance and unrealized synergies. This risk would become apparent if new acquisitions do not meet financial targets or disrupt existing operations.
TMO Recent Earnings History
- Q4 2025
EPS: $6.57 actual vs $6.51 estimate (beat) · Revenue: $12,215M actual vs $12,069M estimate
- Q3 2025
EPS: $5.79 actual vs $5.5 estimate (beat) · Revenue: $11,122M actual
- Q2 2025
EPS: $5.36 actual vs $5.23 estimate (beat) · Revenue: $10,855M actual
- Q1 2025
EPS: $5.15 actual vs $5.1 estimate (beat) · Revenue: $10,364M actual
- Q4 2024
EPS: $6.1 actual vs $5.94 estimate (beat) · Revenue: $11,395M actual
Analyst Price Targets for TMO
The current spread of analyst price targets and ratings for Thermo Fisher Scientific Inc. (TMO).
Reflects the most recently tracked analyst ratings for TMO and may lag real-time updates. Not a recommendation to buy or sell.
TMO Competitive Positioning
Thermo Fisher Scientific Inc. (TMO) is tracked alongside these names in Diagnostics & Research on DailyIQ.
What Moves TMO Stock?
Thermo Fisher Scientific's stock performance is primarily driven by demand across its life sciences, diagnostics, and biopharma services segments. Investor focus remains on the company's ability to innovate and expand its offerings, particularly in high-growth areas like drug discovery and clinical diagnostics.
Diagnostics Growth
Thermo Fisher's diagnostics segment benefits from new product introductions and increasing demand for advanced disease detection tools. Recent launches, such as color-based culture media for Candida species, aim to accelerate diagnostic timelines and improve patient outcomes.
Successful adoption of these innovative diagnostic solutions can lead to increased market share and revenue growth. Any perceived delays or competitive pressures in this segment could negatively impact investor sentiment and the stock price.
Biopharma Services
The company's biopharma services, including its Cryo-Electron Microscopy Drug Discovery Center, are crucial for supporting pharmaceutical and biotech clients. These services are essential for accelerating drug development pipelines, a key area of investment for many life science companies.
Expansion and utilization of these advanced research facilities directly translate to revenue and earnings potential. Strong demand for these services supports Thermo Fisher's growth narrative, while any underutilization or competitive threats could pressure the stock.
Analyst Sentiment
Analyst ratings and price targets play a significant role in shaping short-term stock movements. While TMO has a history of beating earnings estimates, recent adjustments, such as Goldman Sachs' price target reduction, can signal shifts in Wall Street's outlook.
Positive analyst commentary and upward revisions typically boost investor confidence and stock prices. Conversely, price target cuts or downgrades can lead to increased selling pressure, especially if accompanied by concerns about future growth or market conditions.
Key insight: Thermo Fisher Scientific's stock is a play on innovation and expansion within the life sciences and diagnostics sectors. Investor confidence hinges on the successful commercialization of new technologies and the company's ability to maintain its growth trajectory amidst evolving market dynamics and analyst sentiment.
Key Metrics for TMO
Thermo Fisher Scientific's performance hinges on its ability to innovate and expand its reach in the diagnostics and research markets. Investors should monitor key operational and financial metrics to gauge TMO's growth trajectory and market leadership.
Revenue Growth: Measures the increase in TMO's total sales quarter-over-quarter and year-over-year. Accelerating revenue growth indicates strong demand for Thermo Fisher's products and services; slowing growth could signal market saturation or competitive pressures. This is crucial for TMO as it reflects the overall health of its diverse business segments and its ability to capture market share.
EPS Growth: Tracks the growth in Thermo Fisher Scientific's earnings per share. Consistent and accelerating EPS growth is a positive sign of profitability and operational efficiency; declining EPS can raise concerns about cost management or revenue generation. This metric directly impacts shareholder value and is a key indicator of TMO's financial performance.
Segment Performance: Analyzes revenue and profit trends within TMO's core segments (e.g., Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Health Services). Strong performance in key growth areas like diagnostics and biopharma services is vital; weakness in any major segment could drag down overall results. Understanding segment dynamics helps investors assess the drivers of TMO's business and its future potential.
R&D Investment: Monitors the level of investment Thermo Fisher Scientific allocates to research and development. Increasing R&D spending suggests a commitment to innovation and future product pipelines; stagnant or declining investment might indicate a slowdown in new product development. For TMO, robust R&D is essential for maintaining its competitive edge in the rapidly evolving scientific and healthcare industries.
Free Cash Flow: Measures the cash generated by TMO after accounting for capital expenditures. Strong and growing free cash flow provides flexibility for reinvestment, acquisitions, and shareholder returns; declining FCF could limit these options. This metric is important for TMO as it demonstrates the company's ability to generate cash to fund its operations and strategic initiatives.
Frequently Asked Questions About TMO
Is Thermo Fisher Scientific (TMO) stock a good investment?
Thermo Fisher Scientific (TMO) is a leading provider of scientific research and laboratory solutions. Its investment appeal often centers on its broad portfolio serving life sciences, diagnostics, and biopharma, coupled with a strong distribution network. Investors might consider TMO's consistent performance and market position when evaluating its potential.
What drives Thermo Fisher Scientific (TMO) stock price?
The stock price of Thermo Fisher Scientific (TMO) is influenced by factors such as demand for its scientific instruments, reagents, and services across life sciences and healthcare. Growth in its biopharma services segment and the adoption of its diagnostic solutions are key drivers. Overall market sentiment towards the healthcare and biotechnology sectors also plays a significant role.
Does Thermo Fisher Scientific (TMO) pay a dividend?
Yes, Thermo Fisher Scientific (TMO) does pay a quarterly dividend to its shareholders. While the dividend yield may not be the primary attraction for growth-oriented investors, it represents a component of total shareholder return. Investors should review the company's dividend history and payout ratio for consistency and sustainability.
What is Thermo Fisher Scientific's (TMO) valuation?
Thermo Fisher Scientific's (TMO) valuation can be assessed using metrics like its P/E ratio, which stands at approximately 27.8. This figure should be compared against industry peers and the company's historical valuation multiples. The market capitalization of roughly $186 billion also indicates its significant scale within the healthcare sector.
What are the risks of investing in Thermo Fisher Scientific (TMO)?
Risks associated with Thermo Fisher Scientific (TMO) include intense competition within the scientific and healthcare industries, potential regulatory changes affecting diagnostics and biopharma services, and global economic slowdowns impacting research and development spending. Supply chain disruptions and the successful integration of acquisitions also pose challenges.
What is the investment thesis for Thermo Fisher Scientific (TMO)?
The investment thesis for Thermo Fisher Scientific (TMO) typically revolves around its dominant position in providing essential tools and services to the life sciences and healthcare industries. Its diversified business model, spanning instruments, consumables, and services, positions it to benefit from long-term trends in scientific discovery, diagnostics, and biopharmaceutical production.
How is Thermo Fisher Scientific (TMO) performing in its key segments?
Thermo Fisher Scientific (TMO) demonstrates strong performance across its core segments, including life sciences solutions, diagnostics, and laboratory products and services. Recent reports indicate accelerating EPS growth and consistent revenue increases, driven by demand in areas like drug discovery and clinical diagnostics. The company's ability to innovate and expand its offerings, such as new diagnostic tools, underpins its operational strength.
What are Thermo Fisher Scientific's (TMO) growth catalysts?
Key growth catalysts for Thermo Fisher Scientific (TMO) include continued expansion in biopharma services, the development and adoption of advanced diagnostic technologies, and its leadership in analytical instruments. Investments in areas like cryo-electron microscopy and its focus on precision healthcare are also expected to drive future growth.
How does Thermo Fisher Scientific (TMO) compare to its peers?
Thermo Fisher Scientific (TMO) competes in a landscape with large, diversified healthcare companies like UnitedHealth Group (UNH) and Johnson & Johnson (JNJ), as well as specialized biopharmaceutical firms like Eli Lilly (LLY). TMO differentiates itself through its comprehensive offering of laboratory products, instruments, and services essential for research and diagnostics, rather than direct drug development or healthcare provision.
What is Thermo Fisher Scientific's (TMO) outlook for the future?
Thermo Fisher Scientific's (TMO) forward outlook appears positive, supported by ongoing innovation and strategic expansions. Investors will be closely monitoring management's guidance regarding the integration of new product launches and the company's capacity to sustain its growth momentum. Factors such as evolving market conditions and analyst sentiment will also shape future performance.
Learn More
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
Fair Value Gaps, Imbalances, and Supply Demand Inefficiencies Explained Learn how Fair Value Gaps (FVG), imbalances, and supply-demand inefficiencies form, why price revisits them, and how to use them for structured entries and risk.
Advanced Chart Analysis: Scaling, Volume, and Comparative Charting Explained A comprehensive guide to advanced chart construction including arithmetic vs logarithmic scales, dual y-axes, multi-line comparisons, and volume-based charting techniques.
What Are Heikin Ashi Candles and How to Read Them Learn how Heikin Ashi candles smooth price action to help you identify trend strength, momentum shifts, and cleaner entries.
How Is Bitcoin Priced? Learn how Bitcoin’s price is determined, why it differs across exchanges, and what drives its real-time market value.
Break of Structure (BOS) and Change of Character (CHoCH) Explained Learn how Break of Structure (BOS) and Change of Character (CHoCH) reveal trend continuation and reversals - and how smart money traders use them with liquidity and imbalances.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).